We determined the in vitro activity of SMT19969 and 11 comparators, including metronidazole, vancomycin and fidaxomicin, against 107 C. difficile isolates of different antimicrobial resistance phenotypes. Fidaxomicin and SMT19969 were most active. Geometric mean fidaxomicin and SMT19969 MICs were highest in ribotypes known to show multiple resistance. Co-resistance to linezolid and moxifloxacin was evident in ribotypes 001, 017, 027 and 356. High-level ceftriaxone resistance in ribotypes 356 and 018 was location-linked
This manuscript version is made available under the CC-BY-NC-ND 4.0 license: http://creativecommon...
Objectives Clostridioides difficile (CD) is widely reported as one of the most prevalent multi-drug...
A 10-day course of oral fidaxomicin (200 mg twice a day [b.i.d.]), a potent new macrocyclic drug, wa...
Objectives: SMT19969 is a novel antimicrobial under clinical development for the treatment of Clostr...
Treatments for Clostridium difficile infection remain limited, despite the introduction of fidaxomic...
AbstractClostridium difficile infection remains a major healthcare burden. Until the recent introduc...
The comparative in vitro activity of SMT19969, a novel, narrow-spectrum, nonabsorbable agent, was st...
Clostridium difficile infection remains a major healthcare burden. Until the recent introduction of ...
Clostridium difficile infection (CDI) has been primarily treated with metronidazole or vancomycin. H...
Clostridium difficile infection (CDI) has been primarily treated with metronidazole or vancomycin. H...
© The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimic...
Clostridium difficile infection remains a major healthcare burden. Until the recent introduction of ...
Background: Clostridium difficile infection (CDI) is a significant cause of morbidity and mortality ...
OBJECTIVES: In November 2008, a study was performed with support from the European Centre for Diseas...
Background & Objectives: Clostridium difficile is gram-positive rod, spore forming, strict anaerobic...
This manuscript version is made available under the CC-BY-NC-ND 4.0 license: http://creativecommon...
Objectives Clostridioides difficile (CD) is widely reported as one of the most prevalent multi-drug...
A 10-day course of oral fidaxomicin (200 mg twice a day [b.i.d.]), a potent new macrocyclic drug, wa...
Objectives: SMT19969 is a novel antimicrobial under clinical development for the treatment of Clostr...
Treatments for Clostridium difficile infection remain limited, despite the introduction of fidaxomic...
AbstractClostridium difficile infection remains a major healthcare burden. Until the recent introduc...
The comparative in vitro activity of SMT19969, a novel, narrow-spectrum, nonabsorbable agent, was st...
Clostridium difficile infection remains a major healthcare burden. Until the recent introduction of ...
Clostridium difficile infection (CDI) has been primarily treated with metronidazole or vancomycin. H...
Clostridium difficile infection (CDI) has been primarily treated with metronidazole or vancomycin. H...
© The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimic...
Clostridium difficile infection remains a major healthcare burden. Until the recent introduction of ...
Background: Clostridium difficile infection (CDI) is a significant cause of morbidity and mortality ...
OBJECTIVES: In November 2008, a study was performed with support from the European Centre for Diseas...
Background & Objectives: Clostridium difficile is gram-positive rod, spore forming, strict anaerobic...
This manuscript version is made available under the CC-BY-NC-ND 4.0 license: http://creativecommon...
Objectives Clostridioides difficile (CD) is widely reported as one of the most prevalent multi-drug...
A 10-day course of oral fidaxomicin (200 mg twice a day [b.i.d.]), a potent new macrocyclic drug, wa...